ImmuneApproved

Thymogen

Glu-Trp, EW Dipeptide, Glutamyl-Tryptophan

A Khavinson dipeptide bioregulator for thymus and immune system modulation, approved in Russia as an immunomodulator.

Overview

Thymogen (also spelled Thymagen) is a synthetic dipeptide bioregulator composed of L-glutamic acid and L-tryptophan (Glu-Trp or EW). This dipeptide was originally isolated from Thymalin via reversed-phase high-performance liquid chromatography (RP-HPLC) and was later synthesized independently.

As one of the Khavinson peptide bioregulators, Thymogen represents the active immunomodulatory component of thymic extracts in its simplest form. It is approved in Russia as an immunomodulator and has been used clinically for decades.

Molecular Structure

PropertyValue
CompositionL-Glutamyl-L-Tryptophan (Glu-Trp)
AbbreviationEW
TypeSynthetic dipeptide
ClassificationPeptide bioregulator
OriginIsolated from Thymalin

Mechanism of Action

T-Cell Modulation

Alpha-glutamyl-tryptophan stimulates cellular immunity through:

  • T-lymphocyte precursor differentiation: Promotes maturation into immunocompetent cells
  • CD4+/CD8+ ratio normalization: Balances T-helper/T-suppressor populations
  • Cyclic AMP elevation: Increases intracellular cAMP in T-lymphocyte precursors
  • Proliferation stimulation: Enhances T-cell multiplication

Molecular Mechanisms

The dipeptide EW regulates:

  • Gene expression of immune-related proteins
  • Heat-shock protein synthesis
  • Cytokine production and signaling
  • Fibrinolysis pathways
  • Cellular differentiation, proliferation, and apoptosis

Phagocytic Enhancement

Thymogen also affects innate immunity:

  • Normalizes phagocytic activity of macrophages
  • Enhances neutrophil function
  • Supports overall adaptive immune efficacy

Clinical Applications

Approved Uses (Russia)

Thymogen has demonstrated efficacy in:

  • Viral hepatitis: Restoration of immune reactivity
  • Tuberculosis: Adjunct immunotherapy
  • Influenza and ARVI: Acute respiratory infections
  • Pseudotuberculosis: Complex therapy
  • Papillomatosis: Immune support
  • Sepsis: Severe infection management

Immunodeficiency Models

In research models of immunodeficiency (stress, infection, radiation, chemotherapy), Thymogen:

  • Normalizes lymphocyte counts
  • Restores T-cell subpopulations
  • Enhances phagocytic activity
  • Improves adaptive immunity markers

Comparison with Thymalin

FeatureThymogenThymalin
ComplexitySimple dipeptideComplex extract
SynthesisFully syntheticNatural origin
SpecificityTargeted T-cell effectsBroader immunomodulation
CostLowerHigher
Research backingExtensiveExtensive

Both peptides are used for similar indications, with Thymogen representing a more defined molecular approach.

Safety Profile

Thymogen has a favorable safety profile:

  • Low toxicity: Rapidly metabolized to natural amino acids
  • No accumulation: Short biological half-life
  • Minimal side effects: Well-tolerated in clinical use
  • Safe for viral infections: No interference with antiviral responses

The rapid metabolism to L-glutamate and L-tryptophan (natural amino acids) reduces risk of long-term toxicity or accumulation.

Potential Research Applications

Cancer Research

Thymogen may support immune surveillance:

  • Enhanced T-cell responses to abnormal cells
  • Potential adjunct to immunotherapy
  • No reported interference with chemotherapy

COVID-19 Considerations

Research suggests thymic peptides including Thymogen may be beneficial in coronavirus infection treatment, primarily through immune function restoration.

Administration

Common research protocols:

  • Routes: Intranasal, intramuscular injection
  • Course duration: Typically 5-10 days
  • Formulations: Nasal spray, injectable solution

Current Research Directions

  • Mechanisms of thymic peptide signaling
  • Optimal combinations with other immunomodulators
  • Applications in immunosenescence
  • Biomarkers for treatment response

Regulatory Status

Thymogen is approved and marketed in Russia. It is not approved by FDA or EMA and is classified as a research compound in most Western jurisdictions.

References

Key sources include the Journal of Bioregulation and Gerontology, PMC publications on thymic peptides, and Russian clinical pharmacology literature.

Explore more peptides in our comprehensive database

Back to Peptide Database